Santhera Pulls EU Filing For Failed DMD Candidate
End Of Road For Company’s DMD Idebenone Hopes, Patients 'Devastated'
Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.
You may also be interested in...
BioMarin plans to resubmit its marketing application for Roctavian to the European Medicines Agency.
Switzerland’s Santhera is to restructure its business and seek extra funding after the failure of Puldysa (idebenone) in a Phase III Duchenne muscular dystrophy study at interim analysis.
Santhera needs more time to address concerns regarding its current EU application for idebenone in the DMD setting but the Swiss biotech is keeping its sights on a broader indication.